A recent study highlights the impact of parvovirus B19 infections on pediatric patients with sickle cell disease, revealing that genotype and hydroxyurea treatment significantly influence disease severity. This research underscores the need for tailored treatment approaches in managing infections in this vulnerable population.
parvovirus b19 infections in paediatric sickle cell disease patients genotype and hydroxyurea treatment influence disease severity
Original title: “Parvovirus B19 infections in paediatric sickle cell disease patients: Genotype and hydroxyurea treatment influence disease severity.”